Lobbying Filing Details

Total Spending

$0

Activities

3

Lobbyists

3

Gov't Entities

0

Filing Information
Filing UUID:
94453c3a-c305-43e2-a4fe-92baff2a7357
Type:
RA - Registration - Amendment
Period:
2023 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
April 10, 2023 at 5:53 PM
Income:
$0
Expenses:
$0
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Joseph Devaney
Registrant
ASTELLAS PHARMA US, INC.

Pharmaceuticals

Northbrook, Illinois
Client
ASTELLAS PHARMA US, INC.
Illinois, United States of America
Lobbying Activities (3)
Activity 1
Copyright/Patent/Trademark

Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).

Lobbyists (3)
  • JAMES ROLLINS
  • JONATHAN OEHMEN
  • AKSHAI DATTA
Activity 2
Health Issues

Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).

Lobbyists (3)
  • JAMES ROLLINS
  • JONATHAN OEHMEN
  • AKSHAI DATTA
Activity 3
Medicare/Medicaid

Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).

Lobbyists (3)
  • JAMES ROLLINS
  • JONATHAN OEHMEN
  • AKSHAI DATTA
Foreign Entities (1)
ASTELLAS PHARMA INC. (THROUGH 100% OWNERSHIP OF ASTELLAS US HOLDING, INC.)

2-3-11, Nihonbashi-Honcho, Chuo-ku

Contribution: $0

Ownership: 100.0%

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.